Genomics Industry: Myriad Genetics, Inc. – Product Pipeline Review – Q4 2010

• Publication date: December 2010

- Product Pipeline Review - Q4 2010” provides a detailed overview on the firm ’s research and development focus. The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and f...

- Product Pipeline Review - Q4 2010” provides a detailed overview on the firm ’s research and development focus. The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.

Scope of the Research

- Myriad Genetics, Inc. - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Myriad Genetics, Inc. human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Myriad Genetics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Myriad Genetics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Myriad Genetics, Inc.’s strategic position with total access to detailed data on its product pipeline.
- Assess the growth opportunities of Myriad Genetics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Myriad Genetics, Inc.’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Myriad Genetics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Myriad Genetics, Inc. and identify potential opportunities in those areas.

Global Genomics Industry

Table of Contents
Data table of Contents 2
List of Tables 4
List of Figures 4
Myriad Genetics, Inc. Snapshot 5
Myriad Genetics, Inc. Overview 5
Key Information 5
Key Facts 5
Myriad Genetics, Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
Myriad Genetics, Inc. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Myriad Genetics, Inc. – Pipeline Products Glance 10
Myriad Genetics, Inc. Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
Myriad Genetics, Inc.–Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Myriad Genetics, Inc. – Drug Profiles 12
MPC-2130 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
MPI-442690 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Myriad Genetics, Inc. – Pipeline Products by Molecule Type 14
Myriad Genetics, Inc. - Dormant Projects 15
Myriad Genetics, Inc. - Discontinued Pipeline Products 16
Discontinued Pipeline Product Profiles 16
MPC-2130 16
Myriad Genetics, Inc. – Firms Statement 17
Myriad Genetics, Inc. – Operations and Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
January 25, 2010: Myriad Genetics Presents Study Results For Chemotherapy Regimens of FOLFOX6 and FOLFOX6 Plus Avastin 20
January 25, 2010: Myriad Genetics Presents Study Results For Chemotherapy Regimens of FOLFOX6 and FOLFOX6 Plus Avastin 20
January 25, 2010: Myriad Genetics Presents Study Results For Chemotherapy Regimens of FOLFOX6 and FOLFOX6 Plus Avastin 21
October 19, 2005: Myriad Genetics Advances Drug Candidate For Chemotherapy-Induced Nausea 22
September 29, 2005: Myriad Genetics Discovers COB1 Gene For Early-Onset Obesity 23
September 29, 2005: Myriad Genetics Discovers COB1 Gene For Early-Onset Obesity 23
December 02, 2003: Maxim Pharmaceuticals Licenses November el Cancer Therapeutic Candidate MX90745 To Myriad Genetics 24
December 02, 2003: Maxim Pharmaceuticals Licenses November el Cancer Therapeutic Candidate MX90745 To Myriad Genetics 24
December 02, 2003: Maxim Pharmaceuticals Licenses November el Cancer Therapeutic Candidate MX90745 To Myriad Genetics 25
December 02, 2003: Maxim Pharmaceuticals Licenses November el Cancer Therapeutic Candidate MX90745 To Myriad Genetics 25
Financial Deals Landscape 27
Myriad Genetics, Inc., Deals Volume Summary, from 2004 to 2010 27
Myriad Genetics, Inc., Merger and Acquisition Deal Summary By Region, from 2004 to 2010 28
Myriad Genetics, Inc., Merger and Acquisition Deal Summary , from 2004 to 2010 29
Myriad Genetics, Inc. Detailed Deal Summary 30
Asset Purchase 30
Myriad Pharmaceuticals Takes Over Bevirimat From Panacos Pharmaceuticals 30
Acquisition 32
Myriad Genetics Takes Over NaturNorth Technologies 32
Equity Offering 33
Myriad Genetics Completes Public Offering Of US$ 107.7 Mln 33
Myriad Genetics Completes Public Offering Of US$ 50.2 Mln 35
Lundbeck Enters Into Co-March keting Agreement With Myriad Genetics 37
Epigenomics Enters Into Co-Development Agreement With Myriad Genetics 38
Myriad Genetics Enters Into Co-Development Agreement With Abbott Laboratories 39
Myriad Genetics Extends Co-Development Agreement With Abbott Laboratories 40
Myriad Genetics Enters Into Collaboration Agreeement With Pharmaceutical Firms 41
Myriad Genetics Expands Co-Development Agreement With Abbott Laboratories 42
Licensing Agreements 43
Myriad Genetics Enters Into Licensing Agreement With Johns Hopkins University 43
Myriad Genetics Enters Into Licensing Agreement With Saladax Biomedical 44
Myriad Genetics Enters Into Licensing Agreement With Salmedix 45
Myriad Genetics Enters Into Licensing Agreement With Pharmaceutical Firms 46
Myriad Genetics Enters Into Licensing Agreement With Chemicon International 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 49
Contact Us 49
Disclaimer 49

List of Tables
Myriad Genetics, Inc. – Pipeline by Therapy Area and Indication, 2010 7
Myriad Genetics, Inc. – Pipeline by Stage of Development, 2010 8
Myriad Genetics, Inc. – Monotherapy Products in Pipeline, 2010 9
Myriad Genetics, Inc. - Phase I, 2010 10
Myriad Genetics, Inc. – Pipeline By Molecule Type, 2010 14
Myriad Genetics, Inc. - Dormant Developmental Projects, 2010 15
Myriad Genetics, Inc. - Discontinued Pipeline Products, 2010 16
Myriad Genetics, Inc., Subsidiaries 19
Myriad Genetics, Inc., Merger and Acquisition Deal Summary , from 2004 to 2010 27
Myriad Genetics, Inc., Merger and Acquisition Deal Summary by Region, from 2004 to 2010 28
Myriad Genetics, Inc., Merger and Acquisition Deal Summary , from 2004 to 2010 29

List of Figures
Myriad Genetics, Inc. – Pipeline by Therapy Area and Indication, 2010 7
Myriad Genetics, Inc. – Pipeline by Stage of Development, 2010 8
Myriad Genetics, Inc. – Monotherapy Products in Pipeline, 2010 9